Skip to main content

Table 3 Proportion of patients who achieved therapy effectiveness and individual criteria at 1 year of follow-up (n = 16,305)

From: Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study

Effectiveness criteria DMARDs TNFi ± DMARDs Non-TNF biologics ± DMARDs Tofacitinib ± DMARDs
Percent 95% CI Percent 95% CI Percent 95% CI Percent 95% CI
Effective therapy (satisfied all six criteria) 11.1 10.1–12.1 18.6 17.9–19.4 19.8 18.2–21.4 15.4 6.6–24.2
Criterion 1
High adherence
26.6 25.1–28.0 44.0 43.0–44.9 53.3 51.3–55.3 27.7 16.8–38.6
Criterion 2
No biologic or tofacitinib switch or addition
72.7 71.2–74.1 64.3 63.4–65.2 82.1 80.5–83.6 84.6 75.8–93.4
Criterion 3
No DMARD switch or addition
85.3 84.2–86.5 96.1 95.8–96.5 95.5 94.6–96.3 98.5 95.5–100
Criterion 4
No increase in dose or frequency of index drug
92.0 91.1–92.9 94.0 93.5–94.4 88.9 87.6–90.1 100.0a
Criterion 5
No more than one glucocorticoid joint injection
91.3 90.3–92.2 88.8 88.2–89.4 72.8 71.0–74.6 87.7 79.7–95.7
Criterion 6
No new/increased oral glucocorticoid dose
81.4 80.2–82.7 83.3 82.6–84.1 78.0 76.3–79.7 76.9 66.7–87.2
  1. DMARD Disease-modifying antirheumatic drug, TNFi Tumor necrosis factor inhibitors
  2. aStandard tofacitinib dose is usually not increased